Non-small cell lung cancer: disease control rate may be a more powerful predictor of survival than tumor shrinkage
August 23rd, 2006
Researchers evaluate the effectiveness of a new antitumoral therapy by looking at how tumors respond to it. But in the case of advanced non-small cell lung cancer ( NSCLC ), there may be a better way to assess effectiveness. A new Southwest Oncology Group ( SWOG ) study, led by a team of researchers at University of California Davis Cancer Center, suggests that an alternative measurement – “disease control rate” – may be a more powerful predictor of survival than tumor shrinkage.